A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04607655 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Due to COVID-19 pandemic and change in the clinical development strategy for the GB1211 compound

Conditions

Interventions

Sponsor

Galecto Biotech AB

Collaborators